eXoZymes, Inc. (EXOZ)
| Market Cap | 37.13M -65.9% |
| Revenue (ttm) | n/a |
| Net Income | -10.19M |
| EPS | -1.20 |
| Shares Out | 9.28M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 24,353 |
| Open | 4.600 |
| Previous Close | 4.600 |
| Day's Range | 3.705 - 4.881 |
| 52-Week Range | 3.705 - 18.400 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 12, 2026 |
About EXOZ
eXoZymes, Inc. operates as a development stage biotechnology company. It focuses on the development of enzyme modules and cell-free exozyme biosolutions for synthetic biology manufacturing. The company was formerly known as Invizyne Technologies, Inc. and changed its name to eXoZymes, Inc. in February 2025. eXoZymes, Inc. was incorporated in 2014 and is headquartered in Monrovia, California.
Financial Performance
Financial StatementsNews
Water Tower Research Publishes Initiation of Coverage Report on eXoZymes, Inc., "Converting Cell-Free Science into a Scalable and Repeatable Commercial Opportunity"
October 2, 2026, ST. PETERSBURG, FL – Water Tower Research (www.watertowerresearch.com) has published an Initiation of Coverage Report on eXoZymes, Inc. (NASDAQ: EXOZ) titled, “Converting Cell-Free Sc...
eXoZymes Proxy statement: Proxy filing
eXoZymes filed a proxy statement on September 28, 2026, providing details for shareholder voting and corporate governance matters.
eXoZymes Proxy statement: Proxy filing
eXoZymes filed a proxy statement on September 28, 2026, providing details for shareholder voting and corporate governance matters.
eXoZymes Selects Curia as Commercial-Scale Manufacturing Partner for NCT
Program expected to commence in Q4 2026 and establish a roadmap for larger-scale production in 2027 LOS ANGELES, CA / ACCESS Newswire / September 8, 2026 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZyme...
eXoZymes Inc trading halted, volatility trading pause
15:52 EDT eXoZymes (EXOZ) Inc trading halted, volatility trading pause
eXoZymes Earnings Call Transcript: Q2 2026
NCT manufacturing achieved a 10x productivity breakthrough, improving economics and commercial readiness. Cash position strengthened to $5.65M after $6.59M in new financing, supporting operations through 2026. Strategic focus on high-value nutraceuticals and pharmaceuticals, with NCT market launch targeted for H1 2027.
eXoZymes Quarterly report: Q2 2026
eXoZymes has published its Q2 2026 quarterly earnings report on August 20, 2026.
eXoZymes Earnings release: Q2 2026
eXoZymes released its Q2 2026 earnings on August 20, 2026, summarizing the period's financial results.
eXoZymes Reports Second Quarter 2026 Results and Provides Business Update at 5PM ET Today
Management to host Q2 2026 update at 5PM ET / 2PM PT, today. LOS ANGELES, CA / ACCESS Newswire / August 20, 2026 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-enhanced enzymes th...
eXoZymes' NCT Process Achieves 10-fold Productivity Increase, Advancing Beyond Original Commercial-scale Economic Targets
Optimized process delivered a 10-fold improvement in productivity, significantly improving the estimated economics of future commercial-scale manufacturing. Estimated manufacturing cost equivalent has...
eXoZymes to Host Second Quarter 2026 Update Conference Call on Thursday, August 20, 2026
Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-enhanced enzymes that transform abundant feedstock into valuable nutraceuticals and novel medicines - announced the plan to host a web...
eXoZymes Selected for DoE's Genesis Mission to Advance AI-Powered Digital Twins for Cell-Free Biomanufacturing
Company to collaborate with Lawrence Berkeley National Laboratory on AI-enabled digital twins designed to accelerate optimization of enzyme-driven manufacturing processes. The 9-month project awarded ...
eXoZymes Inc trading halted, volatility trading pause
09:35 EDT eXoZymes (EXOZ) Inc trading halted, volatility trading pause
eXoZymes Awarded $2 Million NIH Grant to Advance Cannabinoid Analogs for Drug Discovery
Award allows eXoZymes to expand its portfolio of proprietary new-to-nature molecules and potential future pharmaceutical assets and validates the Company's ability to make rare cannabinoids and new ca...
eXoZymes Inc. Announces Closing of $6 Million Public Offering
LOS ANGELES, CA / ACCESS Newswire / June 17, 2026 / eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes" or "Company"), a pioneer of AI-enhanced enzymes that transform abundant feedstock into valuable nutraceutica...
eXoZymes prices 592,270 shares at $18.00 in public offering
eXoZymes (EXOZ) announced the pricing of its public offering of units, each consisting of two shares of common stock and one common stock purchase warrant. The Company has sold 592,270…
eXoZymes Inc. Announces Pricing of Public Offering of Common Stock and Warrants
LOS ANGELES, CA / ACCESS Newswire / June 8, 2026 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes" or "Company") - a pioneer of AI-enhanced enzymes that transform abundant feedstock into valuable nutra...
eXoZymes Quarterly report: Q1 2026
eXoZymes has published its Q1 2026 quarterly earnings report on May 14, 2026.
eXoZymes announces graduation from Shell GameChanger Accelerator
eXoZymes (EXOZ) announced its graduation from the Shell GameChanger Accelerator, a multimillion-dollar, multiyear program developed in collaboration between Shell and the U.S. Department of Energy’s N...
eXoZymes Announces Graduation from Shell GameChanger(TM) Accelerator Powered by NLR (GCxN) Program
LOS ANGELES, CA / ACCESS Newswire / May 7, 2026 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-enhanced enzymes that transform abundant feedstock into nutraceuticals, novel medici...
eXoZymes Slides: Investor presentation
eXoZymes has posted slides in relation to its latest quarterly earnings report, which was published on May 7, 2026.
eXoZymes CCO, Damien Perriman, Outlines NCTx Strategy and the Commercial Path for Cell-Free Biomanufacturing on Grow Everything Podcast
LOS ANGELES, CA / ACCESS Newswire / April 10, 2026 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-enhanced enzymes that transforms abundant feedstock into valuable nutraceuticals ...
eXoZymes Slides: Investor presentation
eXoZymes has posted slides in relation to its latest quarterly earnings report, which was published on April 10, 2026.